Alghamdi HA et al., 2022-09: Rat chemoprevention study in DMH-induced colon carcinogenesis reporting that low-dose ivermectin (0.25-1 mg/kg) raised glutathione, shifted Bax/caspase-3 up and Bcl-2 down, and reduced tumour histology scores.
A total of 40 male rats were randomly divided into 8 groups (5 rats/group)
n/a (HTML full text, Experimental design)
Alghamdi HA et al., 2022-09: Rat chemoprevention study in DMH-induced colon carcinogenesis reporting that low-dose ivermectin (0.25-1 mg/kg) raised glutathione, shifted Bax/caspase-3 up and Bcl-2 down, and reduced tumour histology scores. Study type: DMH-induced colon cancer in male Wistar rats (chemoprevention design; ivermectin given for 10 weeks, carcinogen DMH 40 mg/kg subcutaneously twice weekly for 5 weeks). N: 40 rats, 8 groups of 5. Country: Saudi Arabia (King Saud University, Riyadh). Dose: 0.25, 0.5 and 1 mg/kg daily for 10 weeks (doses set from the reported LD50 of 50 mg/kg). Comparator: saline negative control and DMH-only positive control. Declared COI: none. Note this is a prevention model at very low doses, not a treatment model of established tumours. Excerpt is a methods record field. Study type: animal.
